In EGFR mutation-positive advanced NSCLC patients, first-line erlotinib followed by cisplatin-gemcitabine was found to show a better survival benefit over first-line chemotherapy followed by second-line erlotinib [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.